Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension

References

• ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA2003289182363236912746359
   PubMed Web of Science ®Google Scholar
• EganBMZhaoYAxonRNUS trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008JAMA2010303202043205020501926
   PubMed Web of Science ®Google Scholar
• HeidenreichPATrogdonJGKhavjouOAForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation2011123893394421262990
   PubMed Web of Science ®Google Scholar
• RogerVLGoASLloyd-JonesDMHeart disease and stroke statistics – 2012 update: a report from the American Heart AssociationCirculation20111251e2e22022179539
   PubMed Web of Science ®Google Scholar
• MoscaLBankaCLBenjaminEJEvidence-based guidelines for cardiovascular disease prevention in women: 2007 updateCirculation2007115111481150117309915
   PubMedGoogle Scholar
• MelloniCBergerJSWangTYRepresentation of women in randomized clinical trials of cardiovascular disease preventionCirc Cardiovasc Qual Outcomes20103213514220160159
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMEvansJCLevyDHypertension in adults across the age spectrum: current outcomes and control in the communityJAMA2005294446647216046653
   PubMed Web of Science ®Google Scholar
• ManciaGGrassiGSystolic and diastolic blood pressure control in antihypertensive drug trialsJ Hypertens20022081461146412172300
   PubMed Web of Science ®Google Scholar
• ZanchettiARuilopeLMAntihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?J Hypertens200220112099211012409940
   PubMed Web of Science ®Google Scholar
• CopleyJBRosarioRHypertension: a review and rationale of treatmentDis Mon20055110–1154861416360376
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding per-indopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• MurphyJCosterGIssues in patient complianceDrugs19975467978009421690
   PubMed Web of Science ®Google Scholar
• GehiAKAliSNaBWhooleyMASelf-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul studyArch Intern Med2007167161798180317846400
   PubMedGoogle Scholar
• SokolMCMcGuiganKAVerbruggeRREpsteinRSImpact of medication adherence on hospitalization risk and healthcare costMed Care200543652153015908846
   PubMed Web of Science ®Google Scholar
• ErdineSCompliance with the treatment of hypertension: the potential of combination therapyJ Clin Hypertens (Greenwich)2010121404620047629
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• DominoFJImproving adherence to treatment for hypertensionAm Fam Physician200571112089209015952435
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• GuptaAKArshadSPoulterNRCompliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysisHypertension201055239940720026768
   PubMed Web of Science ®Google Scholar
• DicksonMPlauschinatCACompliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapyAm J Cardiovasc Drugs200881455018303937
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med2005165101147115215911728
   PubMedGoogle Scholar
• HessGHillJLauHDastaniHChaudhariPMedication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapyPT20083311652666
   PubMedGoogle Scholar
• WaldDSLawMMorrisJKBestwickJPWaldNJCombination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trialsAm J Med2009122329030019272490
   PubMed Web of Science ®Google Scholar
• QuanAChavanuKMerkelJA review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studiesAm J Cardiovasc Drugs20066210311316555863
   PubMedGoogle Scholar
• McInnesGTAntihypertensive drugs in combination: additive or greater than additive?J Hum Hypertens2007211291491617700727
   PubMed Web of Science ®Google Scholar
• YangWChangJKahlerKHEvaluation of compliance and health care utilization in patients treated with single pill vs free combination antihypertensivesCurr Med Res Opin20102692065207620629600
   PubMed Web of Science ®Google Scholar
• BurnierMBrownREOngSHKeskinaslanAKhanZMIssues in blood pressure control and the potential role of single-pill combination therapiesInt J Clin Pract200963579079819220523
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsNew Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• EspostiLDDi MartinoMSaragoniSPharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapiesJ Clin Hypertens (Greenwich)200462768414872145
   PubMedGoogle Scholar
• CorraoGZambonAParodiADiscontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in ItalyJ Hypertens200826481982418327094
   PubMed Web of Science ®Google Scholar
• BramlagePHasfordJBlood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a reviewCardiovasc Diabetol200981819327149
   PubMed Web of Science ®Google Scholar
• WangWMaLZhangYDengQLiuMLiuLThe combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristicsJ Hum Hypertens201125427127720445570
   PubMed Web of Science ®Google Scholar
• EpsteinBJVogelKPalmerBFDihydropyridine calcium channel antagonists in the management of hypertensionDrugs20076791309132717547473
   PubMed Web of Science ®Google Scholar
• MesserliFHEvolution of calcium antagonists: past, present, and futureClin Cardiol2003262 Suppl 2II121612622321
   PubMed Web of Science ®Google Scholar
• BurnierMTelmisartan: a different angiotensin II receptor blocker protecting a different population?J Int Med Res20093761662167920146864
   PubMed Web of Science ®Google Scholar
• ZhengZLinSShiHA systematic review and meta-analysis of telm-isartan versus valsartan in the management of essential hypertensionJ Clin Hypertens (Greenwich)201012641442120591086
   PubMed Web of Science ®Google Scholar
• SiragyHAngiotensin II receptor blockers: review of the binding characteristicsAm J Cardiol19998410A3S8S10588088
   PubMed Web of Science ®Google Scholar
• MiuraSKarnikSSSakuKReview: angiotensin II type 1 receptor blockers: class effects versus molecular effectsJ Renin Angiotensin Aldosterone Syst20111211720603272
   PubMed Web of Science ®Google Scholar
• SinghBNThe mechanism of action of calcium antagonists relative to their clinical applicationsBr J Clin Pharmacol198621Suppl 2109S121S3530295
   PubMedGoogle Scholar
• ElliottWJRamCVCalcium channel blockersJ Clin Hypertens (Greenwich)201113968768921896151
   PubMed Web of Science ®Google Scholar
• de GasparoMCattKJInagamiTWrightJWUngerTInternational union of pharmacology. XXIII. The angiotensin II receptorsPharmacol Rev200052341547210977869
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFMazzottaGGentileGReboldiGThe renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reductionVasc Health Risk Manag20084597198119183745
   PubMedGoogle Scholar
• TuckMLAngiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma systemCurr Hypertens Rep20057424024316061040
   PubMed Web of Science ®Google Scholar
• MoriHOkadaYAraoTNishidaKTanakaYTelmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patientsAdv Ther201229763564422821644
   PubMed Web of Science ®Google Scholar
• KakutaHSudohKSasamataMYamagishiSTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Res2005251414615864875
   PubMedGoogle Scholar
• MallatSGWhat is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?Cardiovasc Diabetol2012113222490507
   PubMed Web of Science ®Google Scholar
• MeredithPAElliottHLClinical pharmacokinetics of amlodipineClin Pharmacokinet199222122311532771
   PubMed Web of Science ®Google Scholar
• StangierJSuCARothWPharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patientsJ Int Med Res200028414916711014323
   PubMed Web of Science ®Google Scholar
• StangierJSchmidJTurckDAbsorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteersJ Clin Pharmacol20004012 Pt 11312132211185629
   PubMed Web of Science ®Google Scholar
• AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138 Suppl B92017970613
   PubMed Web of Science ®Google Scholar
• TWYNSTA (telmisartan and amlodpine besylate) [package insert]Ingelheim, GermanyBoehringer Ingelheim2011
   Google Scholar
• NohYHLimHSKimMJPharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteersClin Ther20123471625163522721873
   PubMed Web of Science ®Google Scholar
• StangierJSuCAPharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteersJ Clin Pharmacol20004012 Pt 11347135411185633
   PubMed Web of Science ®Google Scholar
• TEKAMLO (aliskiren hemifumarate and amlodipine besylate) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2010
   Google Scholar
• CristovamPCArnoniCPde AndradeMCACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cellsExp Biol Med (Maywood)200823381035104318480420
   PubMed Web of Science ®Google Scholar
• KokaVWangWHuangXRKim-MitsuyamaSTruongLDLanHYAdvanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complicationsCirculation2006113101353136016520412
   PubMed Web of Science ®Google Scholar
• LavrentyevENEstesAMMalikKUMechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cellsCirc Res2007101545546417626897
   PubMed Web of Science ®Google Scholar
• SinghVPLeBBhatVBBakerKMKumarRHigh-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytesAm J Physiol Heart Circ Physiol20072932H939H94817483239
   PubMed Web of Science ®Google Scholar
• HoritaYTauraKTaguchiTFurusuAKohnoSAldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathyNephrology (Carlton)200611546246617014562
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPKakafikaAITziomalosKKaragiannisAAngiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?Expert Opin Pharmacother20078552953517376010
   PubMed Web of Science ®Google Scholar
• GreeneLJSpadaroACMartinsARPerussi De JesusWDCamargoACBrain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and IIHypertension1982421781846175571
   PubMed Web of Science ®Google Scholar
• WelchesWRSantosRAChappellMCBrosnihanKBGreeneLJFerrarioCMEvidence that prolyl endopeptidase participates in the processing of brain angiotensinJ Hypertens1991976316381653799
   PubMed Web of Science ®Google Scholar
• YamamotoKChappellMCBrosnihanKBFerrarioCMIn vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive ratsHypertension1992196 Pt 26926961317352
   PubMed Web of Science ®Google Scholar
• SantosRAFerreiraAJSimoesESACRecent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axisExp Physiol200893551952718310257
   PubMed Web of Science ®Google Scholar
• FerreiraAJMurcaTMFraga-SilvaRACastroCHRaizadaMKSantosRANew cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor axisInt J Hypertens2012201214782522319643
   PubMedGoogle Scholar
• IyerSNFerrarioCMChappellMCAngiotensin-(1–7) contributes to the antihypertensive effects of blockade of the renin-angiotensin systemHypertension1998311 Pt 23563619453328
   PubMed Web of Science ®Google Scholar
• DavieAPMcMurrayJJEffect of angiotensin-(1–7) and bradykinin in patients with heart failure treated with an ACE inhibitorHypertension199934345746010489393
   PubMed Web of Science ®Google Scholar
• SukumaranVVeeraveeduPTGurusamyNTelmisartan acts through the modulation of ACE-2/ANG 1–7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditisLife Sci2012907–828930022210452
   PubMed Web of Science ®Google Scholar
• NeldamSEdwardsCLangMJonesRLong-term tolerability and efficacy of single-pill combinations of telmisartan 40–80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5–10 mg: Open-label, long-term follow-ups of the TEAMSTA-5 and TEAMSTA-10 studiesCurr Ther Res Clin Exp2012731–26584
   PubMed Web of Science ®Google Scholar
• FogariRDerosaGZoppiAEffect of telmisartan–amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuriaAm J Hypertens200720441742217386350
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdMajulCROlveraRTelmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial studyPostgrad Med2009121251419332958
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMaffoliPLazzariPMugelliniADerosaGEffect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patientsExpert Opin Pharmacother201112162441244821958068
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEffect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover studyExpert Opin Pharmacother20111291351135821510830
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed-dose combinations in the treatment of hypertension: the cycle repeatsDrugs200262344346211827559
   PubMed Web of Science ®Google Scholar
• TEKTURNA (aliskiren hemifumarate) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2007
   Google Scholar
• NeldamSLangMJonesRTelmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 studyJ Clin Hypertens (Greenwich)201113745946621762357
   PubMed Web of Science ®Google Scholar
• WhiteWBLittlejohnTWMajulCREffects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertensionBlood Press Monit201015420521220613496
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdMajulCROlveraRResults of treatment with telmisartan–amlodipine in hypertensive patientsJ Clin Hypertens (Greenwich)200911420721319614805
   PubMed Web of Science ®Google Scholar
• SharmaAMBakrisGNeutelJMSingle-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, doubleblind trialClin Ther201234353755122386829
   PubMed Web of Science ®Google Scholar
• BekkiHYamamotoKSoneMEfficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertensionOxid Med Cell Longev20103534234621150340
   PubMed Web of Science ®Google Scholar
• LacourciereYKrzesinskiJMWhiteWBDavidaiGSchumacherHSustained antihypertensive activity of telmisartan compared with valsartanBlood Press Monit20049420321015311147
   PubMed Web of Science ®Google Scholar
• LittlejohnTMroczekWMarburyTVanderMaelenCPDubielRFA prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoringCan J Cardiol20001691123113211021956
   PubMed Web of Science ®Google Scholar
• NixonRMMullerELowyAFalveyHValsartan vs other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approachInt J Clin Pract200963576677519392925
   PubMed Web of Science ®Google Scholar
• National Center for Health StatisticsHealth, United States, 2011: With Special Feature on Socioeconomic Status and HealthW Hyattsville, MD2012
   Google Scholar
• MaLWangWZhaoYCombination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety studyAm J Cardiovasc Drugs201212213714222329591
   PubMed Web of Science ®Google Scholar
• LuFZhaoYLiuZSunHSunSWangSA 48-week study of amlodipine plus amiloride/hydrochlorothiazide vs amlodipine plus telmisartan in the treatment of hypertensionInt J Clin Pract201266879279922805271
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim PharmaceuticalsAn Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose CombinationClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated May 18, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00618774?term=1235.16&rank=1. NLM identifier: NCT00618774Accessed September 24, 2012
   Google Scholar